View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 1, 2021

Coronavirus company news summary – Oxford BioDynamics and Agilent sign agreement and launch EpiSwitch Explorer Array Kit – Abbott receives FDA approval for rapid antigen self-test

By Chloe Kent

Oxford BioDynamics and Agilent Technologies have signed a supply and resale agreement to manufacture and sell the new EpiSwitch Explorer Array Kit. The kit is available for high-resolution 3D genome profiling and biomarker discovery. The EpiSwitch platform has already been used to develop the recently launched Covid-19 Severity Test, EpiSwitch CST.

Abbott has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the over-the-counter, non-prescription, asymptomatic use of its BinaxNOW COVID-19 Ag Self-Test. The test will be available to individuals with or without symptoms and without a prescription. Abbott is expected to start shipping to major food and drug retailers in the coming weeks.

BioVaxys Technology has applied for pre-IND (Investigational New Drug) meeting request and submitted a briefing package with the FDA for Covid-T, its T-cell immune response diagnostic for SARS-CoV-2. BioVaxys expects a written response to its pre-IND briefing package later this month. Covid-T uses delayed-type hypersensitivity (DTH), a measure of T-cell immunity used for other infectious diseases such as fungal diseases, tuberculosis, and mumps.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy